The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Study

American Journal of Clinical Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

---

Exploring the Efficacy, Safety, and Clinical Implications of Deucravacitinib in East Asians with Psoriasis: A Narrative Review

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1746 - 1746

Published: March 5, 2025

Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, has demonstrated strong efficacy in the treatment of moderate-to-severe psoriasis. It works through an allosteric mechanism to selectively inhibit TYK2, leading suppression IL-23/Th17/IL-17 axis and reduction key pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-23. This review focuses on clinical implications deucravacitinib East Asian patients, highlighting its efficacy, safety, differences outcomes compared other populations. Data from pivotal trials POETYK PSO-3 PSO-4, which included populations, robust safety profiles, often surpassing results observed global like PSO-1 PSO-2. Subgroup analyses network meta-analyses further corroborate these findings, providing comprehensive understanding therapeutic potential this demographic. Factors lower body mass index, genetic predispositions, environmental influences may contribute response. The profile is favorable, with low rates serious adverse events stable laboratory parameters. underscores need for research investigate genetic, metabolic, factors that influence outcomes, aiming optimize personalized strategies patients

Language: Английский

---

Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation

Metabolites, Journal Year: 2025, Volume and Issue: 15(3), P. 206 - 206

Published: March 18, 2025

Psoriatic arthritis (PsA) is a chronic inflammatory disease that extends beyond musculoskeletal and dermatologic involvement to elevate cardiometabolic risk. Emerging evidence highlights the critical role of systemic inflammation in metabolic dysregulation, accelerating insulin resistance, dyslipidemia, oxidative stress, all which contribute increased burden cardiovascular PsA. This review explores intricate interplay between mediators—such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17),—adipokine imbalances, lipid metabolism abnormalities, foster endothelial dysfunction atherosclerosis. The dysregulation adipokines, including leptin, adiponectin, resistin, further perpetuates cascades, exacerbating Additionally, alterations seen PsA, particularly resistance dysfunction, not only comorbidities but also impact severity therapeutic response. Understanding these mechanistic links imperative for refining risk stratification strategies tailoring interventions. By integrating targeted immunomodulatory therapies with management, more comprehensive approach PsA treatment can be achieved. Future research must focus on elucidating shared pathways, enabling development innovative mitigate both complications

Language: Английский

---

Comparative effects of biologics on anxiety and depression symptoms in psoriasis

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2025, Volume and Issue: unknown

Published: April 24, 2025

Language: Английский

---

Association of insulin resistance indices with kidney stones and their recurrence in a non-diabetic population: an analysis based on NHANES data from 2007–2018

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: April 24, 2025

To systematically evaluate the association between insulin resistance indices and risk of kidney stones their recurrence in U.S. non-diabetic individuals, while identifying predictive indicators. This cross-sectional study analyzed data from 2007-2018 NHANES. Five IR were calculated. Weighted logistic regression, restricted cubic spline, mediation analyses used to assess independent associations these individuals. 9,605 participants showed an overall incidence 8.63% a rate 2.70%. regression RCS revealed significant positive METs-IR, HOMA-IR, TyG-BMI, recurrence. Every unit increase METs-IR was linked 2% rise (95% CI: 1.014-1.027, p < 0.001) 3.3% 1.018-1.048, 0.001); each HOMA-IR raised by 5% 1.025-1.078, 7.9% 1.041-1.118, 0.001). Adjusting for confounders shifted relationships nonlinear linear (p > 0.05). demonstrated strongest diagnostic accuracy predicting recurrence, with uric acid vitamin D mediating found that elevated (METs-IR, TyG-BMI) significantly increased stone population. Serum mediated this association, best

Language: Английский

---

Molecular mechanisms and drug therapy of metabolism disorders in psoriasis

Journal of Dermatological Treatment, Journal Year: 2024, Volume and Issue: 35(1)

Published: July 16, 2024

Psoriasis is a prevalent skin disease affecting approximately 1%-3% of the population and imposes significant medical, social economic burdens. involves multiple organs often complicated with obesity, diabetes, dyslipidemia, hypertension. Because benefits lipid-lowering agents antidiabetic medications for psoriasis, metabolic abnormalities possibly play pathogenic role in psoriasis.

Language: Английский

---

Association between insulin resistance indices and kidney stones: results from the 2015–2018 National Health and Nutrition Examination Survey

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: Oct. 2, 2024

Objective To explore the association between representative insulin resistance (IR) indices and risk of kidney stone disease in an American adult population. The IR referred to metabolic score for (METS-IR), triglyceride high-density lipoprotein cholesterol (TG/HDL-C) ratio, glucose-body mass index (TyG-BMI), visceral adiposity (VAI), homeostatic model assessment (HOMA-IR). Methods We investigated participants who joined 2015–2018 National Health Nutrition Examination Survey (NHANES) reported histories. Weighted proportions, multivariable regression analysis, restricted cubic splines were used evaluate associations stones after their adjustment gender, age, race, education, smoking status, alcohol drinking frequency, hypertension diabetes physical activity level, water intake, levels calcium, cholesterol, uric acid. Results A total 19,225 included. weighted prevalence was 11.1%. logistic showed a dose–response relationship METS-IR [odds ratio (OR) = 1.02, 95% confidence interval (CI) (1.01, 1.04), p &lt; 0.01]. similar observed TyG-BMI full [OR 1.0, CI (1.0, 1.01), 0.001]. Sex-stratified analyses revealed that nephrolithiasis 1.03, 1.05), 0.01], 1.01, &lt;0.001] significant among male fully adjusted model. Moreover, found 1.06), 0.05] diabetic adjustment. Furthermore, potential nonlinear other (i.e., TG/HDL-C, VAI, HOMA-IR) disease. Conclusion Higher associated with higher nephrolithiasis. Future investigations are required identify role progress formation propose prevention measures health guidelines.

Language: Английский

---

Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome

Clinical Reviews in Allergy & Immunology, Journal Year: 2024, Volume and Issue: 66(3), P. 294 - 315

Published: July 2, 2024

Language: Английский

---

The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression

Diagnostics, Journal Year: 2024, Volume and Issue: 14(24), P. 2887 - 2887

Published: Dec. 23, 2024

Background/Objectives: Psoriasis is a chronic dermatological condition with systemic implications, especially metabolic syndrome (MS). This study evaluated the vicious cycle where obesity and MS exacerbate inflammation that complicates efficacy of psoriasis therapies by examining PASI score over one-year period. Patients were classified into two subgroups: those alone (PSO) both (PSO-MS). Methods: A total 150 patients, half whom also concomitantly presented syndrome, received biologic comprising anti-IL-17, anti-IL-23, anti-TNF-a, or methotrexate, scores assessed at baseline 3, 6, 12 months. Results: All treatments showed significant reductions in PASI; however, patients PSO more marked than PSO-MS group. Anti-IL-17 produced greatest sustained long-term improvements, whereas anti-IL-23 prompt early improvements. Increases BMI leptin concentrations associated modest rate reduction score, underlining impact dysfunction on treatment efficacy. Conclusions: highlights importance managing comorbidities such as psoriasis, interplay between health further therapeutic outcomes.

Language: Английский

---

Insulin resistance and psoriasis

British Journal of Dermatology, Journal Year: 2024, Volume and Issue: 191(4), P. 486 - 487

Published: May 13, 2024

Journal Article Accepted manuscript Insulin resistance and psoriasis Get access Shirley P Parraga, Parraga Wake Forest University School of Medicine, Winston-Salem, NC, USA https://orcid.org/0009-0002-1835-1311 Search for other works by this author on: Oxford Academic Google Scholar Steven R Feldman USACenter Dermatology Research, Department Dermatology, USADepartment Pathology, Social Sciences & Health Policy, Corresponding author: R. Feldman, Email:[email protected] https://orcid.org/0000-0002-0090-6289 British ljae199, https://doi.org/10.1093/bjd/ljae199 Published: 13 May 2024 history Received: 30 April Accepted: 09

Language: Английский

---